Skip to main content

Table 1 Participant characteristics at baseline

From: The use of ultrasensitive quantitative-PCR to assess the impact of primaquine on asymptomatic relapse of Plasmodium vivax infections: a randomized, controlled trial in Lao PDR

VariableDrug allocationTotal, N = 40
Placebo, n = 20Primaquine, n = 20
Age in year, mean (95% CI)31.7 (24.4–39.0)23.4 (17.1–29.6)27.5 (22.6–32.4)
Male (%)14 (70)12 (60)26 (65)
Weight kg, mean (95% CI)44.5 (39.7–49.3)44.6 (38.2–50.9)44.5 (40.6–48.5)
Complete 12-month FU (%)16 (80)16 (80)32 (80)
Hba g/dl, mean (95% CI)13.7 (13.1–14.4)13.5 (12.9–14.1)13.6 (13.2–14.1)
Age in year, median (Range)32.5 (10–76)19 (10–54)25.5 (10–76)
Weight kg, mean (95% CI)44.5 (39.7–49.3)44.6 (38.2–50.9)44.5 (40.6–48.5)
Recruitment year, n
 Jun-169918
 Jun-17111122
uPCR
 During surveys of MDA trial
  Mono-PV infection161733
  Mixed PV infection437
 At day 0
  PV infection000
  1. aHaemoglobin